Search peptides, terms, sources/

Metabolic Research

Metabolic research covers peptides studied for effects on glucose regulation, insulin sensitivity, fat metabolism and body composition. It asks about metabolic function, not body weight alone. The evidence runs from laboratory work to human randomised trials, and includes a controlled trial with no significant effect. A peptide's presence here is not a confirmed metabolic benefit.

Which peptides have been studied in metabolic research?

  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • KisspeptinMetastin

    Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • MOTS-cMitochondrial open reading…

    16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells. Not licensed in the UK. No published trial gave MOTS-c to people; human studies measured the body's own levels.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Survodutide

    Investigational peptide that activates glucagon and GLP-1 receptors. Not authorised in the UK. Studied in phase 3 trials, all sponsor-funded.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • TesamorelinTH9507

    Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.

    Growth hormone axisHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine

View in the full index

Best recorded finding for each peptide in this area

The best recorded finding for each peptide in this area. Each row grades one finding, not the peptide or the medicine.
PeptideUK statusFindingStudy typeEvidence grade
AOD-9604Not licensed in the UKSix pooled Phase I/II trialsHuman trialModerate
CagrilintideNot licensed in the UKBrain amylin receptor mechanismAnimalPreliminary
KisspeptinNot licensed in the UKNo effect on food intakeHuman trialLimited
LiraglutideLicensed UK medicineSCALE prediabetes progression trialHuman trialModerate
MazdutideNot licensed in the UKPhase 3 in type 2 diabetesHuman trialModerate
MOTS-cNot licensed in the UKDiscovery paper, mice and cellsAnimalPreliminary
RetatrutideNot licensed in the UKLiver fat in MASLDHuman trialLimited
SemaglutideLicensed UK medicineThe SELECT cardiovascular trialHuman trialStrong
SurvodutideNot licensed in the UKLiver fat in obesity with MASLDHuman trialModerate
TesamorelinNot licensed in the UKHIV visceral fat trialHuman trialStrong
TirzepatideLicensed UK medicineObstructive sleep apnoea trialHuman trialStrong

"Metabolic Research" groups peptides investigated for effects on glucose regulation, insulin sensitivity, lipid metabolism, visceral fat and related body-composition markers. It is distinct from the broader Weight Management category in that the underlying research question is metabolic function rather than body-weight outcome specifically, though the two frequently overlap in practice. Evidence spans in-vitro and animal-preclinical mechanistic work through to human randomised controlled trials, and includes at least one case where a controlled human trial testing a metabolic endpoint reported no significant effect. Classification in this area denotes a studied metabolic research question, not a confirmed metabolic benefit.

32 sources in the library relate to this area. See them.

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.